Home › Companies › Aquestive Therapeutics, Inc. › 2025-2026

Aquestive Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Aquestive Therapeutics, Inc.’s Form 8-K, filed 2026-06-10 (Item 5.07 on EDGAR). Page generated 02 October 2026.

8Reported items
163Asset managers
766Fund votes
2026-06-10Meeting date

Proxy season: 2024-2025 2025-2026

Explore Aquestive Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Aquestive Therapeutics, Inc.

These tallies are Aquestive Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-10 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Aquestive Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-10
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: John S. Cochran	36,914,899	--	5,680,845	--	--	Outcome not stated
Elect Director: Abigail L. Jenkins	39,094,166	--	3,501,578	--	--	Outcome not stated
(2) The proposal to approve, on a non-binding advisory basis, executive compensation was approved for the one year.	37,798,609	3,192,381	1,604,754	--	37,465,582	Majority: yes
(3) The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified.	78,804,323	910,690	346,313	--	--	Majority: yes

Source: Aquestive Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-10 — read the filing on EDGAR.

How asset managers voted at the Aquestive Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 163 asset managers that disclosed a Aquestive Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Aquestive Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 37,798,609AGAINST: 3,192,381

Aquestive Therapeutics, Inc.’s own tally for this item (“(2) The proposal to approve, on a non-binding advisory basis, executive compensation was approved for the one year.”): 37,798,609 for, 3,192,381 against, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,450,119 outstanding shares: 30% for, 3% against (33% of the company cast a for/against vote).

The 160 asset managers below cast 99.6% of the shares they voted on this item FOR (30,677,425 for, 100,537 against).

FOR 99.6%

FOR: 30,677,425 (99.7%)AGAINST: 100,537 (0.3%)ABSTAIN: 1,450 (0.0%)

Largest asset managers voting on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at Aquestive Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
RTW INVESTMENTS, LP	7,426,471	0	0	For
Vanguard	3,453,760	7	4	For
BlackRock	2,508,096	41,501	1,269	For
Samsara BioCapital, LLC	2,500,000	0	0	For
Blue Owl Capital Holdings LP	1,207,932	0	0	For
Federated Hermes	1,095,958	0	0	For
Janney Montgomery Scott LLC	1,088,110	0	0	For
WASATCH ADVISORS LP	877,289	0	0	For
State Street	856,341	4,188	0	For
WASATCH FUNDS TRUST	856,623	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	757,139	0	0	For
Bridge Builder Trust	723,482	0	0	For
Two Sigma	688,491	0	0	For
BALYASNY ASSET MANAGEMENT L.P.	659,772	0	0	For
Fidelity	643,647	0	0	For
DAFNA Capital Management LLC	550,915	0	0	For
Charles Schwab	534,820	0	0	For
Bracebridge Capital, LLC	459,216	0	0	For
STIFEL NICOLAUS & CO INC \MO\	385,562	0	0	For
Northern Trust	369,141	0	0	For
Russell Investments	290,665	0	0	For
Latash Investments, LLC	243,134	0	0	For
Simplify Exchange Traded Funds	234,279	0	0	For
Wellington	207,255	0	0	For
MELLON INVESTMENTS Corp	128,696	0	0	For

Showing the 25 largest of 160 asset managers. See all 160 in the interactive database.

2. TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 78,804,323AGAINST: 910,690

Aquestive Therapeutics, Inc.’s own tally for this item (“(3) The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified.”): 78,804,323 for, 910,690 against, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,450,119 outstanding shares: 63% for, 0.8% against (64% of the company cast a for/against vote).

The 41 asset managers below cast 99.9% of the shares they voted on this item FOR (7,799,462 for, 2,495 against).

FOR 99.9%

FOR: 7,799,462 (100.0%)AGAINST: 2,495 (0.0%)ABSTAIN: 1,000 (0.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR” at Aquestive Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	3,280,298	2,483	For
BlackRock	1,020,835	0	For
WASATCH FUNDS TRUST	856,623	0	For
Bridge Builder Trust	723,482	0	For
Fidelity	638,919	0	For
Charles Schwab	267,401	0	For
Simplify Exchange Traded Funds	234,279	0	For
Federated Hermes	156,350	0	For
Russell Investments	97,519	0	For
QUANTITATIVE MASTER SERIES LLC	87,940	0	For
Equitable	83,359	0	For
State Street	80,439	12	For
Lincoln Financial	64,000	0	For
Global X	48,259	0	For
ProShares	28,350	0	For
AIG/SunAmerica	15,722	0	For
SEI	15,400	0	For
AQR	15,077	0	For
DWS	14,058	0	For
Pacific Life	12,053	0	For
Voya	9,501	0	For
Calvert	7,276	0	For
Venerable Variable Insurance Trust	7,126	0	For
Blackstone Alternative Investment Funds	5,200	0	For
Principal	5,060	0	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

3. To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the Board of Directors, each to serve for a three-year term until the Company's 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Abigail L. Jenkins

DIRECTOR ELECTIONS

100% fund support · no official result

FOR 97%

The 27 asset managers below cast 100% of the shares they voted on this item FOR (4,975,620 for, 0 against).

FOR: 4,975,620 (97.1%)ABSTAIN: 150,113 (2.9%)

Largest asset managers voting on “To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the Board of Di” at Aquestive Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	3,271,297	0	For
WASATCH FUNDS TRUST	856,623	0	For
Fidelity	638,919	0	For
Equitable	29,379	53,980	Abstain
State Street	80,392	59	For
Lincoln Financial	64,000	0	For
ProShares	0	28,350	Abstain
AIG/SunAmerica	0	15,722	Abstain
AQR	0	15,077	Abstain
DWS	0	14,058	Abstain
Pacific Life	12,053	0	For
Voya	9,501	0	For
Calvert	0	7,276	Abstain
Blackstone Alternative Investment Funds	0	5,200	Abstain
Principal	0	5,060	Abstain
Goldman Sachs	4,641	0	For
Morgan Stanley	0	4,028	Abstain
PENN SERIES FUNDS INC	2,800	0	For
TIAA	2,287	0	For
Brinker Capital Destinations Trust	2,165	0	For
Nationwide	1,332	0	For
Guggenheim	0	785	Abstain
Direxion Shares ETF Trust	0	308	Abstain
Victory Capital	0	208	Abstain
T. Rowe Price	134	0	For

Showing the 25 largest of 27 asset managers. See all 27 in the interactive database.

4. To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the Board of Directors, each to serve for a three-year term until the Company's 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Gregory B. Brown, M.D.

DIRECTOR ELECTIONS

100% fund support · no official result

FOR 99.8%

The 27 asset managers below cast 100% of the shares they voted on this item FOR (5,118,421 for, 0 against).

FOR: 5,118,421 (99.9%)ABSTAIN: 7,312 (0.1%)

Largest asset managers voting on “To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the Board of Di” at Aquestive Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	3,271,297	0	For
WASATCH FUNDS TRUST	856,623	0	For
Fidelity	638,919	0	For
Equitable	83,359	0	For
State Street	80,415	36	For
Lincoln Financial	64,000	0	For
ProShares	28,350	0	For
AIG/SunAmerica	15,722	0	For
AQR	15,077	0	For
DWS	14,058	0	For
Pacific Life	12,053	0	For
Voya	9,501	0	For
Calvert	0	7,276	Abstain
Blackstone Alternative Investment Funds	5,200	0	For
Principal	5,060	0	For
Goldman Sachs	4,641	0	For
Morgan Stanley	4,028	0	For
PENN SERIES FUNDS INC	2,800	0	For
TIAA	2,287	0	For
Brinker Capital Destinations Trust	2,165	0	For
Nationwide	1,332	0	For
Guggenheim	785	0	For
Direxion Shares ETF Trust	308	0	For
Victory Capital	208	0	For
T. Rowe Price	134	0	For

Showing the 25 largest of 27 asset managers. See all 27 in the interactive database.

5. To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the Board of Directors, each to serve for a three-year term until the Company's 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: John S. Cochran

DIRECTOR ELECTIONS

100% fund support · no official result

FOR 80%ABSTAIN 20%

The 27 asset managers below cast 100% of the shares they voted on this item FOR (4,109,472 for, 0 against).

FOR: 4,109,472 (80.2%)ABSTAIN: 1,016,261 (19.8%)

Largest asset managers voting on “To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the Board of Di” at Aquestive Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	3,271,297	0	For
WASATCH FUNDS TRUST	0	856,623	Abstain
Fidelity	638,919	0	For
Equitable	29,379	53,980	Abstain
State Street	80,368	83	For
Lincoln Financial	64,000	0	For
ProShares	0	28,350	Abstain
AIG/SunAmerica	0	15,722	Abstain
AQR	0	15,077	Abstain
DWS	0	14,058	Abstain
Pacific Life	12,053	0	For
Voya	0	9,501	Abstain
Calvert	0	7,276	Abstain
Blackstone Alternative Investment Funds	0	5,200	Abstain
Principal	0	5,060	Abstain
Goldman Sachs	4,641	0	For
Morgan Stanley	0	4,028	Abstain
PENN SERIES FUNDS INC	2,800	0	For
TIAA	2,287	0	For
Brinker Capital Destinations Trust	2,165	0	For
Nationwide	1,332	0	For
Guggenheim	0	785	Abstain
Direxion Shares ETF Trust	0	308	Abstain
Victory Capital	0	208	Abstain
T. Rowe Price	134	0	For

Showing the 25 largest of 27 asset managers. See all 27 in the interactive database.

6. Elect Abigail Jenkins

DIRECTOR ELECTIONSOutcome not stated

Combines 5 wordings of this item as funds reported it.

— Outcome not stated · no against or withheld count reported

Aquestive Therapeutics, Inc.’s own tally for this item (“Elect Director: Abigail L. Jenkins”): 39,094,166 for; no against or withheld count reported, per its Form 8-K filed 2026-06-10 (Item 5.07).

The 15 asset managers below cast 100% of the shares they voted on this item FOR (2,672,932 for, 0 against).

FOR 99.8%

FOR: 2,672,932 (99.9%)ABSTAIN: 3,291 (0.1%)

Largest asset managers voting on “Elect Abigail Jenkins” at Aquestive Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
BlackRock	1,020,835	0	For
Bridge Builder Trust	723,482	0	For
Charles Schwab	267,401	0	For
Simplify Exchange Traded Funds	234,279	0	For
Federated Hermes	156,350	0	For
Russell Investments	97,519	0	For
QUANTITATIVE MASTER SERIES LLC	87,940	0	For
Global X	48,259	0	For
SEI	15,400	0	For
Vanguard	11,473	10	For
Venerable Variable Insurance Trust	7,126	0	For
Eleva Capital SAS	0	2,720	Abstain
Nationwide	2,301	0	For
Advisors' Inner Circle Fund III	567	0	For
John Hancock	0	561	Abstain

7. Elect Gregory B. Brown

DIRECTOR ELECTIONS

Combines 5 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.6%

The 15 asset managers below cast 100% of the shares they voted on this item FOR (2,668,020 for, 0 against).

FOR: 2,668,020 (99.7%)ABSTAIN: 8,203 (0.3%)

Largest asset managers voting on “Elect Gregory B. Brown” at Aquestive Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
BlackRock	1,020,835	0	For
Bridge Builder Trust	723,482	0	For
Charles Schwab	267,401	0	For
Simplify Exchange Traded Funds	234,279	0	For
Federated Hermes	156,350	0	For
Russell Investments	97,519	0	For
QUANTITATIVE MASTER SERIES LLC	87,940	0	For
Global X	48,259	0	For
SEI	15,400	0	For
Vanguard	3,847	7,636	Abstain
Venerable Variable Insurance Trust	7,126	0	For
Eleva Capital SAS	2,720	0	For
Nationwide	2,301	0	For
Advisors' Inner Circle Fund III	0	567	Abstain
John Hancock	561	0	For

8. Elect John S. Cochran

DIRECTOR ELECTIONSOutcome not stated

Combines 5 wordings of this item as funds reported it.

— Outcome not stated · no against or withheld count reported

Aquestive Therapeutics, Inc.’s own tally for this item (“Elect Director: John S. Cochran”): 36,914,899 for; no against or withheld count reported, per its Form 8-K filed 2026-06-10 (Item 5.07).

The 15 asset managers below cast 100% of the shares they voted on this item FOR (2,496,428 for, 0 against).

FOR 93%

FOR: 2,496,428 (93.3%)ABSTAIN: 179,795 (6.7%)

Largest asset managers voting on “Elect John S. Cochran” at Aquestive Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
BlackRock	1,020,835	0	For
Bridge Builder Trust	723,482	0	For
Charles Schwab	267,401	0	For
Simplify Exchange Traded Funds	234,279	0	For
Federated Hermes	156,350	0	For
Russell Investments	0	97,519	Abstain
QUANTITATIVE MASTER SERIES LLC	87,940	0	For
Global X	0	48,259	Abstain
SEI	0	15,400	Abstain
Vanguard	3,840	7,643	Abstain
Venerable Variable Insurance Trust	0	7,126	Abstain
Eleva Capital SAS	0	2,720	Abstain
Nationwide	2,301	0	For
Advisors' Inner Circle Fund III	0	567	Abstain
John Hancock	0	561	Abstain

Largest Aquestive Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Aquestive Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 125,450,119 shares outstanding at the time of that meeting.

Top Aquestive Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	RTW INVESTMENTS, LP	5.92%
2	Vanguard	2.75%
3	BlackRock	2.03%
4	Samsara BioCapital, LLC	1.99%
5	Blue Owl Capital Holdings LP	0.96%
6	Federated Hermes	0.87%
7	Janney Montgomery Scott LLC	0.87%
8	WASATCH ADVISORS LP	0.70%
9	State Street	0.69%
10	WASATCH FUNDS TRUST	0.68%

Reported Aquestive Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Aquestive Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Douglas K. Bratton	7.86%	DEF14A
BlackRock	5.99%	13F
RTW Investments, LP	4.98%	DEF14A
Vanguard Group	4.70%	13F
MonoLine RX II, L.P.	2.77%	DEF14A
Daniel Barber	2.45%	DEF14A
MonoLine RX III, L.P.	2.12%	DEF14A
State Street	2.03%	13F
Geode Capital	1.92%	13F
MonoLine Partners, L.P.	1.42%	DEF14A

Percentages above are of 125,450,119 shares outstanding, as reported by Aquestive Therapeutics, Inc. on its Form 10-Q dated 2026-05-11 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Aquestive Therapeutics, Inc.’s 10-Q dated 2026-05-11. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Aquestive Therapeutics, Inc.'s shareholder meeting held 2026-06-10, in the 2025-2026 proxy season, 163 asset managers reported how they voted in their SEC Form N-PX filings, covering 766 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 92% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Aquestive Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-10.

Aquestive Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).